<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002265</url>
  </required_header>
  <id_info>
    <org_study_id>031C</org_study_id>
    <secondary_id>N3526A</secondary_id>
    <nct_id>NCT00002265</nct_id>
  </id_info>
  <brief_title>An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492</brief_title>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To demonstrate that zalcitabine (dideoxycytidine; ddC) monotherapy is safe and tolerable in&#xD;
      the treatment of patients with AIDS or advanced AIDS related complex (ARC) who previously&#xD;
      demonstrated intolerance to zidovudine (AZT) treatment while in Protocol N3300 (NIAID ACTG&#xD;
      114) or N3492 (NIAID ACTG 119).&#xD;
&#xD;
      NOTE OF CAUTION FOR CONCOMITANT MEDICATIONS ON STUDY:&#xD;
&#xD;
      Patients on amphotericin, pyrimethamine, sulfadiazine, trimethoprim/sulfamethoxazole,&#xD;
      ganciclovir, intravenous pentamidine, intravenous acyclovir or oral acyclovir or other bone&#xD;
      marrow or renal toxic drugs may not tolerate concomitant ddC. If these drugs are given&#xD;
      concomitantly with ddC, patients should have frequent clinical and laboratory assessments, as&#xD;
      appropriate. Drugs that are nephrotoxic or have the potential to cause peripheral neuropathy&#xD;
      might be expected to cause increased toxicity when co-administered with ddC. Drugs that could&#xD;
      cause serious additive toxicity when co-administered with study medication will be allowed&#xD;
      for treatment of an acute intercurrent illness or opportunistic infection at the discretion&#xD;
      of the investigator. Their use may be allowed with interruption of study drug for up to 35&#xD;
      days per episode, for a total of 90 days for the study. If the patient's condition requires&#xD;
      chronic administration of these medications, the patient will be discontinued from study&#xD;
      medication and followed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zalcitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Recommended:&#xD;
&#xD;
          -  Prophylactic aerosolized pentamidine.&#xD;
&#xD;
          -  Allowed for maintenance after recovering from infection for which initially&#xD;
             prescribed:&#xD;
&#xD;
          -  Pyrimethamine.&#xD;
&#xD;
          -  Sulfadiazine.&#xD;
&#xD;
          -  Amphotericin.&#xD;
&#xD;
          -  Fluconazole.&#xD;
&#xD;
          -  Ketoconazole (= or &lt; 400 mg/day).&#xD;
&#xD;
          -  Acyclovir ( = or &lt; 1000 mg/day).&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Medications for tuberculosis or Mycobacterium avium infection.&#xD;
&#xD;
          -  Allowed:&#xD;
&#xD;
          -  Erythropoietin.&#xD;
&#xD;
          -  Megace.&#xD;
&#xD;
          -  Trimethoprim/sulfamethoxazole &lt; or = 20 mg/kg/day.&#xD;
&#xD;
          -  Nystatin.&#xD;
&#xD;
          -  Low dose acetaminophen or non-steroidal anti-inflammatory agents ( = or &lt; 3 g/day).&#xD;
&#xD;
          -  Medications on which patient has been stable for 14 days prior to study entry.&#xD;
&#xD;
          -  Allowed if no evidence of peripheral neuropathy at study entry:&#xD;
&#xD;
          -  Isoniazid (must be receiving pyridoxine = or &gt; 50 mg/day concomitantly).&#xD;
&#xD;
          -  Phenytoin, if stable for = or &gt; 3 months.&#xD;
&#xD;
          -  Metronidazole with a study medication interruption and pre and post testing for&#xD;
             peripheral neuropathy. Any signs of this and the patient will not be restarted on&#xD;
             study medication.&#xD;
&#xD;
          -  REFER TO NOTE OF CAUTION IN PROTOCOL SUMMARY.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Previously enrolled in NIAID ACTG 114 or NIAID ACTG 119.&#xD;
&#xD;
          -  Experienced = or &gt; grade 3 zidovudine (AZT) related toxicity while enrolled in the&#xD;
             assigned protocol and followed the procedures for the study drug dose reduction,&#xD;
             interruption, rechallenge and permanent discontinuation as per NIAID ACTG 114 or NIAID&#xD;
             ACTG 119.&#xD;
&#xD;
          -  NOTE:&#xD;
&#xD;
          -  After permanent study drug discontinuation from NIAID ACTG 114 the drug code may be&#xD;
             broken ONLY after discussion with Hoffmann-La Roche regarding toxicity management and&#xD;
             probable relationship to AZT. Although NIAID ACTG 119 is an open-label study,&#xD;
             investigators should also contact Hoffmann-La Roche prior to entering any patient into&#xD;
             this protocol.&#xD;
&#xD;
          -  Toxicities must be &quot;probably&quot; AZT related (as determined by the investigator and&#xD;
             following discussion by sponsor) for patients to be eligible for inclusion into this&#xD;
             protocol.&#xD;
&#xD;
          -  Toxicities must be resolved to = or &lt; grade 2 within 45 days of discontinuation from&#xD;
             AZT in NIAID ACTG 114 or NIAID ACTG 119.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  An active AIDS defining opportunistic infection or other active intercurrent illnesses&#xD;
             if their ongoing treatment requires the use of excluded medications (see Exclusion -&#xD;
             Concurrent Medications).&#xD;
&#xD;
          -  Baseline fever &gt; 38.5 C if caused by an occult opportunistic infection or neoplasm and&#xD;
             requiring continuous treatment with excluded medications. If the evaluation for&#xD;
             infection is unrevealing, the patient may be entered after the evaluation is completed&#xD;
             but while mycobacterial cultures are still pending. Patients with a history of&#xD;
             unexplained fever &gt; 38.5 C should be evaluated as above and/or be afebrile (T &lt; 38.0&#xD;
             C) for 2 weeks prior to study entry.&#xD;
&#xD;
          -  Severe AIDS dementia complex as defined by a score of &lt; 23 on the Mini-Mental State&#xD;
             Exam at the time of discontinuation from NIAID ACTG 114 or NIAID ACTG 119.&#xD;
&#xD;
          -  Any history of peripheral neuropathy or moderate to severe peripheral neuropathy as&#xD;
             defined below:&#xD;
&#xD;
          -  A score of = or &gt; 4 in any one category or a score of = or &gt; 2 in two categories of&#xD;
             the peripheral neuropathy segment of the Signs and Symptoms Questionnaire.&#xD;
&#xD;
          -  Accompanied by:&#xD;
&#xD;
          -  Results on the Standardized Neurological exam indicative of a moderate abnormality,&#xD;
             particularly impaired sensation of sharp pain, light touch or vibration in lower&#xD;
             extremities, distal extremity weakness or distal extremity hyporeflexia.&#xD;
&#xD;
          -  Significant cardiac disease, defined as history of ventricular arrhythmias requiring&#xD;
             medication, prior myocardial infarct or history of angina or ischemia changes on EKG.&#xD;
&#xD;
          -  Significant liver disease, as defined by transaminases &gt; 5 x upper limit of normal or&#xD;
             a history of cirrhosis or ascites.&#xD;
&#xD;
          -  Significant renal disease as defined by an estimated creatinine clearance &lt; 50 ml/min.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other antiretroviral agents.&#xD;
&#xD;
          -  Biologic modifiers.&#xD;
&#xD;
          -  Corticosteroids.&#xD;
&#xD;
          -  Other experimental agents including:&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Ribavirin.&#xD;
&#xD;
          -  ddI.&#xD;
&#xD;
          -  Drugs that could cause peripheral neuropathy including:&#xD;
&#xD;
          -  Hydralazine.&#xD;
&#xD;
          -  Nitrofurantoin.&#xD;
&#xD;
          -  Vincristine.&#xD;
&#xD;
          -  Cisplatin.&#xD;
&#xD;
          -  Dapsone.&#xD;
&#xD;
          -  Disulfiram.&#xD;
&#xD;
          -  Diethyldithiocarbamate.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  An active AIDS defining opportunistic infection or other active intercurrent illnesses&#xD;
             if their ongoing treatment requires the use of excluded medications (see Exclusion -&#xD;
             Concurrent Medications). Such patients will be allowed into the study if they have&#xD;
             completed therapy with an excluded concomitant medication and are stable for 14 days.&#xD;
             Had to discontinue study medication in NIAID ACTG 114 or NIAID ACTG 119 because of an&#xD;
             opportunistic infection or intercurrent illness which required continuous treatment&#xD;
             with medications allowed for concomitant administration in NIAID ACTG 114 or ACTG 119.&#xD;
             Symptoms and conditions defined in patient Exclusion - Co-Existing Condition. Active&#xD;
             substance or alcohol abuse. Unwillingness or deemed unable to sign informed consent.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Radiation therapy.&#xD;
&#xD;
        Active substance or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Davies Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Zion Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr for Special Immunology</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Robert Swartz</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Service</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hosp</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graduate Hosp</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humana Hosp / Med City Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 1994</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Zalcitabine</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zalcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

